Effect of Immunosuppressive and Other Drugs on the Cortisol-cortisone Shuttle in Human Kidney and Liver

Abstract

Background: Impaired 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) has been suggested in patients with hypertension or renal disease, where it may contribute to sodium retention and hypertension. 11β-HSD1, which is expressed predominantly in liver and adipose tissue, influences glucose homeostasis and fat distribution by altering intracellular cortisol (F) concentrations. We tested immunosuppressive drugs that cause hypertension, and substances that interfere with steroidogenesis or influence glucose homeostasis for their ability to influence the inhibition of 11β-HSD isozymes.

Methods: For inhibition experiments, we used microsomes prepared from unaffected parts of human liver segments and resected human kidney cortex because of hepatocarcinoma or renal cell cancer. The inhibitory potency of several compounds was evaluated in concentrations from 10^-9-10^-5 mol/l.

Results: Only sirolimus, but not cyclosporine A, tacrolimus, mycophenolate mofetil, or azathioprine showed a slight inhibition of 11β-HSD2 activity. None of the drugs that inhibit steroidogenesis (suramine, mitotane, etomidate, and aminogluthethimide) or steroid metabolism (rifampicine) influenced 11β-HSDs, nor did ginsenoides Re, Rc, and Rb1. Among sulfonylureas, only gliclazide decreased significantly 11β-HSD1 activity.

Conclusions: Increased blood pressure due to immunosuppressive drugs is probably not caused by direct inhibition of 11β-HSD2. An additional glucose lowering effect of sulfonylurea gliclazide may be due to its ability to inhibit 11β-HSD1.

Key words

11β-hydroxysteroid - dehydrogenases - aldosterone - cortisol - drugs - obesity - sulfonylureas - mineralocorticoid receptor

References

• 1 Tannin GM, Agarwal AK, Monder C, New MI, White PC. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization.  J Biol Chem. 1991;  266 16653-16658
• 2 Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11b-hydroxysteroid dehydrogenase type 2 enzyme.  Mol Cell Endocrinol. 1994;  105 R11-R17
• 3 Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.  Endocr Rev. 2004;  25 831-866
• 4 Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.  Proc Nat Acad Sci USA. 1997;  94 14924-14929
• 5 Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.  Science. 1987;  237 268-275
• 6 Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.  Science. 1988;  242 583-585
• 7 Edwards CR, Stewart PM, Burt D, Brett L, MacIntyre MA, Sutanto WS, Kloet ER de, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor.  Lancet. 1988;  2 986-989
• 8 Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.  J Clin Invest. 1988;  82 340-349
• 9 Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle.  J Clin Endocrinol Metab. 2003;  88 2384-2392
• 10 Quinkler M, Zehnder D, Lepenies J, Petrelli MD, Moore JS, Hughes SV, Cockwell P, Hewison M, Stewart PM. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.  Eur J Endocrinol. 2005;  153 291-299
• 11 Pretorius E, Wallner B, Marx J. Cortisol resistance in conditions such as asthma and the involvement of 11beta-HSD-2: a hypothesis.  Horm Metab Res. 2006;  38 368-376
• 12 Quinkler M, Johanssen S, Grossmann C, Bahr V, Muller M, Oelkers W, Diederich S. Progesterone metabolism in the human kidney and inhibition of 11beta- hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites.  J Clin Endocrinol Metab. 1999;  84 4165-4171
• 13 Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bahr V, Oelkers W. In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I.  Eur J Endocrinol. 2000;  142 200-207
• 14 Mariniello B, Ronconi V, Sardu C, Pagliericcio A, Galletti F, Strazzullo P, Palermo M, Boscaro M, Stewart PM, Mantero F, Giacchetti G. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension.  Am J Hypertens. 2005;  18 1091-1098
• 15 Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus.  Clin Nephrol. 1998;  49 356-363
• 16 Friemann S, Feuring E, Padberg W, Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.  Transplant Proc. 1998;  30 1240-1242
• 17 Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.  Kidney Int. 2003;  63 43-52
• 18 eppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombes M. Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation.  Endocrinology. 2002;  143 1932-1941
• 19 Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.  Clin Transplant. 2004;  18 186-192
• 20 Heering P, Grabensee B. Influence of ciclosporin A on renal tubular function after kidney transplantation.  Nephron. 1991;  59 66-70
• 21 Julien J, Farge D, Kreft-Jais C, Guyene TT, Plouin PF, Houssin D, Carpentier A, Corvol P. Cyclosporine-induced stimulation of the renin-angiotensin system after liver and heart transplantation.  Transplantation. 1993;  56 885-891
• 22 Ferrer-Martinez A, Felipe A, Barcelo P, Casado FJ, Ballarin J, Pastor-Anglada M. Effects of cyclosporine A on Na, K-ATPase expression in the renal epithelial cell line NBL-1.  Kidney Int. 1996;  50 1483-1489
• 23 Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review.  J Am Soc Nephrol. 1999;  10 1366-1380
• 24 Schroth M, Plank C, Rauh M, Dorr HG, Rascher W, Dotsch J. Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure.  Eur J Endocrinol. 2006;  154 555-561
• 25 Lambert A, Frost J, Mitchell R, Wilson AU, Robertson WR. On the site of action of the anti-adrenal steroidogenic effect of etomidate and megestrol acetate.  Clin Endocrinol (Oxf). 1984;  21 721-727
• 26 Preziosi P, Vacca M. Adrenocortical suppression and other endocrine effects of etomidate.  Life Sci. 1988;  42 477-489
• 27 Ayub M, Stitch SR. Effect of ketoconazole on placental aromatase, 3 beta-hydroxysteroid dehydrogenase-isomerase and 17 beta-hydroxysteroid dehydrogenase.  J Steroid Biochem. 1986;  25 981-984
• 28 Ashby H, DiMattina M, Linehan WM, Robertson CN, Queenan JT, Albertson BD. The inhibition of human adrenal steroidogenic enzyme activities by suramin.  J Clin Endocrinol Metab. 1989;  68 505-508
• 29 Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma.  Clin Endocrinol (Oxf). 2004;  60 273-287
• 30 Macdonald IA, Roach PD. Bile induction of 7 alpha- and 7 beta-hydroxysteroid dehydrogenases in Clostridium absonum.  Biochim Biophys Acta. 1981;  665 262-269
• 31 Salehi M, Ferenczi A, Zumoff B. Obesity and cortisol status.  Horm Metab Res. 2005;  37 193-197
• 32 Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component.  Diabetes. 2002;  51 1851-1858
• 33 Chung SH, Choi CG, Park SH. Comparisons between white ginseng radix and rootlet for antidiabetic activity and mechanism in KKAy mice.  Arch Pharm Res. 2001;  24 214-218
• 34 Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus.  Drugs. 2004;  64 1339-1358
• 35 Muller G, Wied S. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro.  Diabetes. 1993;  42 1852-1867
• 36 Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.  J Clin Endocrinol Metab. 1999;  84 3140-3145
• 37 ter Braak EW, Appelman AM, van dT, I, Erkelens DW, Haeften TW van. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia.  Diabetes Care. 2002;  25 107-112
• 38 Glowka FK, Hermann TW, Zabel M. Bioavailability of gliclazide from some formulation tablets.  Intern J. Pharmaceutics. 1998;  172 71-77

Correspondence